Sagamore Investments
Sagamore Investments is an investment firm established in 2002, headquartered in Beijing, China, with additional offices in Shanghai and Hong Kong. The firm specializes in direct investments as well as fund of funds, focusing on venture capital, growth capital, and late-stage private equity. It primarily targets high-growth sectors aligned with China's consumption upgrade, including fintech, healthcare, artificial intelligence, and education. Sagamore Investments typically seeks to take a majority stake in its direct investments, emphasizing its commitment to fostering growth in these dynamic industries within China.
Stealth BioTherapeutics
Convertible Note in 2018
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of therapies targeting diseases linked to mitochondrial dysfunction. Founded in 2006 and based in George Town, Cayman Islands, the company is advancing its lead product candidate, Elamipretide, which aims to address both rare genetic and age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide that stabilizes mitochondrial structure and function during oxidative stress, and SBT-272, a compound under evaluation for rare neurodegenerative diseases, including amyotrophic lateral sclerosis. Mitochondria play a crucial role in energy production and overall organ function, making the company's focus on these organelles significant in the biopharmaceutical landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.